Introduction
============

Patients with T1-2N0 early glottic cancer (EGC) have shown excellent local control and survival rates after undergoing either radiotherapy (RT) or surgical treatment \[[@b1-roj-2019-00143]\]. The probability of lymph node metastasis is low in EGC; thus, localized RT to the larynx can successfully treat EGC with voice quality preservation and low toxicity levels \[[@b2-roj-2019-00143]\]. RT is therefore the preferred treatment option among these patients \[[@b1-roj-2019-00143],[@b3-roj-2019-00143]\].

Several studies have investigated the importance of prognostic factors that can affect RT outcomes in patients with EGC, such as fraction size, total dose, and overall treatment time \[[@b4-roj-2019-00143]-[@b6-roj-2019-00143]\]. Some investigators have attempted to identify altered fractionated schedules. Better results have been reported for hypofractionated radiotherapy (HFX; a fraction size of more than 2.0 Gy) than for conventional fractionated radiotherapy (CFX; a fraction size of 1.8--2 Gy) \[[@b7-roj-2019-00143]-[@b11-roj-2019-00143]\]. However, the optimal fraction size, total dose, and treatment schedule are still unclear; furthermore, there is a lack of sufficient data regarding treatment of EGC by HFX performed using advanced techniques such as intensity-modulated radiotherapy (IMRT) and/or simultaneous integrated boost (SIB) technique \[[@b12-roj-2019-00143]\]. Therefore, we analyzed the clinical and dosimetric outcomes of patients with EGC who received HFX with or without SIB technique at our institution.

Materials and Methods
=====================

1. Patients
-----------

We analyzed 85 patients with EGC who were treated with hypofractionated RT between January 2011 and December 2016. The inclusion criteria were as follows: (1) histologically and clinically confirmed EGC (cT1-2N0M0); (2) RT as a curative treatment; (3) availability to undergo laryngoscopy during RT and follow-up; (4) no prior RT administered to the neck. The stage of cancer was determined according to the 7th edition of the American Joint Committee on Cancer. Histologic characteristics and stromal invasion of tumor were confirmed via biopsy. This study was approved by the Institutional Review Board of Kyungpook National University Hospital (No. KNUH2017-09-021-001) and Kyungpook National University Chilgok Hospital (No. KNUCH2017-10-010).

2. Radiotherapy
---------------

Patients were immobilized in the supine position with a thermoplastic mask. For planning computed tomography (CT)-scan, slice thickness of 3 mm was used. For patients who received three-dimensional conformal radiotherapy (3D CRT), the clinical target volume (CTV1) included the whole larynx from the inferior margin of the hyoid bone to the cricoid cartilage, and the planning target volume (PTV1) was defined as CTV1 + 1 cm. For IMRT plan, CTV1 and PTV1 were the same volumes as those of 3D CRT. Among 66 patients receiving IMRT, SIB was performed in 43 patients, most of whom (76.7%) had at least one of the factors including anterior commissure involvement, stromal invasion, or T2 stage. An additional planning target volume (PTV2) for SIB was generated by extending 0.5 cm from CTV2, which was expanded by 0.5 cm from the tumor.

In this study, the prescription dose to the PTV of the whole larynx (PTV1) was 60.75 Gy in 27 fractions of 2.25 Gy in all cases. In the patients receiving IMRT with SIB, radiation doses of 2.25 Gy for PTV1 and 2.3--2.5 Gy for PTV2 per fraction were administered with the aim of tumor dose escalation. The carotid arteries were extended 1.5 cm craniocaudally to the PTV1. A 3D CRT was administered using two opposite parallel fields with or without a paired wedge and by modulating the field weight or performing dose normalization to improve target coverage. In IMRT, nine beam angles of 280°--80° or 250°--110° were used, and the beam numbers, directions, and weights were adapted to avoid the spinal cord and enhance conformity and homogeneity of dose distribution. IMRT plans were normalized such that the PTV of the whole larynx (PTV1) received \>95% of the prescription dose without an intention of carotid artery sparing. SIB plan was calculated by adding the PTV1 and the dose difference between the PTV1 and PTV2.

3. Evaluation of treatment outcome and toxicity
-----------------------------------------------

Patients were regularly evaluated by performing laryngoscopy and physical examinations during the treatment period and at routine follow-up visits. Post-treatment imaging studies included a CT scan at 2 months after RT and a positron emission tomography-CT scan at 3 months after RT. Acute and late toxicities were graded using the National Cancer Institute Common Toxicity Criteria version 4.0 from the start of RT. Furthermore, we analyzed dose-volume data, such as V~35Gy~ and V~50Gy~, for the carotid arteries to predict complications caused by radiation exposure to the carotid arteries \[[@b13-roj-2019-00143]\].

4. Statistical analyses
-----------------------

The primary endpoints were locoregional recurrence-free survival (LRFS). The secondary endpoints were overall survival (OS) and HFX toxicity. LRFS was defined as the time from the date of the end of RT to the date of the diagnosis of local and/or regional disease failure. OS was defined as the duration between the date of the end of RT and the date of death from any cause. Disease control and survival rates were calculated using the Kaplan--Meier method and were compared using the log-rank test. A chi-square or Fisher exact test was used to compare the categorical variables between the treatment groups with or without SIB. We performed univariate and multivariate Cox proportional hazards analyses to evaluate the effect of variables on LRFS and OS. Mann--Whitney U test was used to compare the difference in carotid artery doses between 3D CRT and IMRT. The biologically effective dose (BED) was calculated according to the linear-quadratic model.

Results
=======

Patient and tumor characteristics are listed in [Table 1](#t1-roj-2019-00143){ref-type="table"}. The median patient age was 65 years (range, 43 to 86 years). Clinical T1 and T2 diseases were observed in 70 (82.4%) and 15 (17.6%) patients, respectively. Eighteen patients (21.2%) had tumors with stromal invasion and 51 (60.0%) had tumors with an anterior commissure involvement. For the PTV of gross tumors, 37 patients received a total BED~10~ of 84.38 Gy~10~, whereas the remaining 48 patients (56.5%) received a total BED~10~ of \<84.38 Gy~10~. The median overall treatment time was 38 days (range, 36 to 62 days). Altogether, 66 patients were treated with IMRT and 19 patients were treated with 3D CRT.

The median follow-up duration was 29.9 months (range, 5.5 to 76.5 months). All patients achieved complete remission after a median of 50 days from the end of RT (range, 14 to 206 days). The 5-year rates of LRFS and OS were 88.1% and 86.2%, respectively ([Fig. 1A](#f1-roj-2019-00143){ref-type="fig"}, [1B](#f1-roj-2019-00143){ref-type="fig"}). Clinical T stage (cT1 vs. cT2) was a statistically significant factor in the univariate and multivariate analyses for LRFS (hazard ratio \[HR\] = 7.917; and confidence interval \[CI\], 2.104--29.787; p = 0.006). However, clinical T stage was not associated with OS (p = 0.881). Age, gender, RT aim (which means recurrent disease or not), anterior commissure involvement, stromal invasion, RT technique, SIB and BED~10~ (Gy) for tumor did not affect LRFS and OS ([Table 2](#t2-roj-2019-00143){ref-type="table"}).

Disease failure was observed in 9 patients (10.6%), local failure occurred only in 6 patients (7.1%), locoregional failure occurred in 9 patients (10.6%), and combined regional and distant failure but without local failure occurred in 1 patient (1.2%). The median time to disease failure after the end of RT was 9.1 months (range, 2.4 to 20.1 months). Salvage surgery was conducted in seven patients, and the other patients did not receive it. One patient received a second surgery owing to rapid locoregional tumor progression during adjuvant neck RT after the first salvage surgery. Distant metastasis was observed in one patient after salvage surgery. This patient had multiple metastatic lesions in the right cervical and mediastinal lymph nodes, pericardium, both lungs, left adrenal gland, and sacrum; the patient died 7 days after the diagnosis of distant disease failure. Of the 85 patients, 7 patients died. Two events of cancer-specific death (97.6%) occurred.

Most patients had grade 1 or 2 mucositis and dermatitis during the treatment. Grade 2 chronic laryngeal edema was observed in two patients. No patients experienced acute or chronic toxicities of ≥grade 3. In the plan analysis of IMRT and 3D CRT for the carotid arteries, the mean of V~35Gy~ was 35.4% (range, 0.0% to 70.5%) for IMRT plans, and 59.8% (range, 31.9% to 87.6%) for 3D CRT plan. The mean of V~50Gy~ was 22.2% (range, 0.0% to 44.3%) for the IMRT plan, and 40.5% (range, 7.5% to 73.6%) for the 3D CRT plan. Carotid artery dose was more significantly lowered by IMRT than by 3D CRT (V~35Gy~, p \< 0.001; V~50Gy~, p \< 0.001).

Discussion and Conclusion
=========================

In this study, the 5-year rates of LRFS and OS were 88.1% and 86.2%, respectively. These results are comparable with those of other studies involving HFX \[[@b7-roj-2019-00143],[@b9-roj-2019-00143]-[@b11-roj-2019-00143],[@b14-roj-2019-00143]-[@b16-roj-2019-00143]\] ([Table 3](#t3-roj-2019-00143){ref-type="table"}). Le et al. \[[@b9-roj-2019-00143]\] and Yu et al. \[[@b11-roj-2019-00143]\] identified that fraction size was an important prognostic factor for local control. Some studies used a fraction size of 2.25 Gy, which is similar to the fraction size used in our study. Yamazaki et al. \[[@b10-roj-2019-00143]\] reported the outcomes of a randomized trial which analyzed 180 patients with T1 glottic cancer, with a 5-year local control rate of 77% for CFX and 92% for HFX (p = 0.004). The authors concluded that HFX using a radiation dose of 2.25 Gy for a shorter duration showed superior local control than CFX. The KROG-0201 trial \[[@b16-roj-2019-00143]\], a prospective randomized trial, compared HFX (63 Gy in 28 fractions for T1; 67.5 Gy in 30 fractions for T2) with CFX (66 Gy in 33 fractions for T1; 70 Gy in 35 fractions for T2). The local progression-free survival at 5 years was 77.8% for CFX and 88.5% for HFX, but the difference was insignificant (p = 0.213). Those studies reported no significant differences in complication rates between the HFX and CFX arms. Therefore, 2.25 Gy per fraction may be an acceptable fraction size for the whole larynx. Additionally, a study conducted in Yale University analyzed data for EGC patients treated with RT from the National Cancer Database \[[@b17-roj-2019-00143]\]. The authors reported that the use of HFX was associated with better survival than that using CFX, especially for clinical T2 EGC.

Some authors have reported the use of large fraction sizes exceeding 2.5 Gy \[[@b7-roj-2019-00143],[@b8-roj-2019-00143],[@b18-roj-2019-00143]\]. These studies delivered a total dose of approximately 50 Gy in 16 fractions over 3 weeks \[[@b8-roj-2019-00143],[@b18-roj-2019-00143]\] and 55 Gy in 20 fractions over 4 weeks \[[@b7-roj-2019-00143]\], with median follow-up durations of 5--7 years. In a study by Ermis et al. \[[@b7-roj-2019-00143]\], the 5-year local control rate was 85.6%. Gowda et al. \[[@b8-roj-2019-00143]\] reported a 5-year local control rate of 93%, whereas Cheah et al. \[[@b18-roj-2019-00143]\] reported a 5-year locoregional control rate of 88%. There were acceptable complications, and the cancer-specific survival at 5 years was 95.7%--97% in these studies. However, a larger fraction size may cause an increase in adverse complications. After a long follow-up duration of ≥5 years, a higher risk of late complications was found for patients who received RT with a large fraction size of \>3 Gy \[[@b19-roj-2019-00143]\]. Dinshaw et al. \[[@b20-roj-2019-00143]\] reported that radiation-induced edema occurred in 20% of the T2 patients treated with a fraction size of 3.3 Gy.

IMRT using SIB has already been widely used in the treatment of head and neck cancer owing to its radiobiologic advantages caused by tumor dose escalation and better target dose distribution with lower organs at risk (OAR) dose \[[@b21-roj-2019-00143],[@b22-roj-2019-00143]\], and Janssen et al. \[[@b23-roj-2019-00143]\] reported positive results of SIB-IMRT for glottic cancer. We used a fraction size of 2.25 Gy to treat EGC, and attempted to achieve a tumor dose escalation of 2.3--2.5 Gy per fraction by SIB-IMRT. Use of SIB technique for the tumor did not affect LRFS (p = 0.191), which suggests that the larynx may be treated in EGC without administration of an additional higher radiation dose of SIB for the tumor.

Anterior commissure (AC) involvement is often considered to be an unfavorable prognostic factor. The AC is connected to the thyroid cartilage, which lacks a tumor barrier \[[@b9-roj-2019-00143]\]. Thus, a tumor with AC involvement may easily penetrate the thyroid cartilage and spread to surrounding tissues. However, there are conflicting reports of AC involvement as a significant prognostic factor \[[@b8-roj-2019-00143],[@b11-roj-2019-00143],[@b15-roj-2019-00143],[@b16-roj-2019-00143],[@b24-roj-2019-00143],[@b25-roj-2019-00143]\]. In our study, no significant difference in locoregional control was observed for AC involvement (p = 0.603).

The analyses conducted by Kim et al. \[[@b15-roj-2019-00143]\] and Moon et al. \[[@b16-roj-2019-00143]\] revealed no significant effect of T2 disease. However, in our study, T2 disease was the only significant predictor of locoregional disease control (p = 0.002). The 10-year local control rate was 82% and 57% for T1 and T2 diseases (p = 0.00) in a study by Dinshaw et al. \[[@b20-roj-2019-00143]\]. As mentioned earlier, SIB was mostly administered to patients who had at least one of the factors including anterior commissure involvement, stromal invasion, or T2 stage at our institution.

The overall treatment time, which is closely connected with the fraction size, is a very important prognostic factor \[[@b5-roj-2019-00143],[@b9-roj-2019-00143],[@b26-roj-2019-00143]\]. A larger fraction size facilitates a shorter overall treatment time, which is required to diminish the accelerated repopulation of tumor cells \[[@b27-roj-2019-00143]\]. In an analysis of 91 patients with T1 glottic cancer, Rudoltz et al. \[[@b5-roj-2019-00143]\] found that a dose per fraction of ≥2 Gy provided superior local control than that achieved with a conventional dose per fraction of \<2 Gy. The authors also reported that a prolonged overall treatment time was associated with a decline in local control rate: 100% within 42 days, 91% for 43--46 days, 74% for 47--50 days, 65% for 51--54 days, and 50% for 55--66 days (p = 0.0001). Onimaru et al. \[[@b26-roj-2019-00143]\] used a cutoff of 46 days for the overall treatment time of T1 glottic cancer, which showed a significant difference before and after the cutoff (p = 0.0349). In our study, the treatment of 80 patients was completed within 46 days, even if there were 7 cases of locoregional recurrences among them. However, the results of this study may not be comparable because of the inclusion of T2 and recurrent diseases.

RT may increase the risk of cerebrovascular accidents (CVA) \[[@b13-roj-2019-00143]\]. Although there was no patient in the present study who had CVA after RT, a higher risk of fatal CVA after RT was reported in patients receiving RT than the risk associated with surgery for EGC in the Surveillance, Epidemiology, and End Results (SEER) database (2.8% vs. 1.5%, p = 0.037) \[[@b28-roj-2019-00143]\]. Other SEER analyses revealed an increased incidence of CVA in elderly EGC patients at approximately 8% in patients receiving RT than surgery \[[@b29-roj-2019-00143],[@b30-roj-2019-00143]\]. There are a variety of ways to prevent carotid artery delineation and dose constraint \[[@b31-roj-2019-00143]\]. Most studies suggest a distance of 1--2.5 cm from PTV as the superior and inferior extent of the carotid artery \[[@b31-roj-2019-00143]-[@b33-roj-2019-00143]\]. In our study, the carotid artery was considered to be the single OAR. We used a 1.5-cm extension craniocaudally from PTV, which is similar to the procedure implemented in studies by Kim et al. \[[@b33-roj-2019-00143]\] and Matthiesen et al. \[[@b34-roj-2019-00143]\]. Although the planning procedures for IMRT in our study were performed without the intent of carotid artery preservation, IMRT showed lower V~35Gy~ and V~50Gy~ of the carotid artery than did 3D CRT (p \< 0.001). These dosimetric advantages of IMRT may not be inferior to those reported by Berwouts et al. \[[@b12-roj-2019-00143]\] and Janssen et al. \[[@b23-roj-2019-00143]\]. Consequently, IMRT may decrease the dose for OARs exposed to CFX ([Fig. 2](#f2-roj-2019-00143){ref-type="fig"}). Our study included clinical experiences for IMRT, which is valuable because most studies on HFX were implemented using 2D/3D technique, and many IMRT studies were focused on the dosimetric aspect of EGC \[[@b7-roj-2019-00143],[@b9-roj-2019-00143]-[@b11-roj-2019-00143],[@b14-roj-2019-00143]-[@b16-roj-2019-00143],[@b31-roj-2019-00143]\].

There are some limitations to our study because of its retrospective design. The number of patients was relatively small, and the median follow-up duration was short. Further comprehensive studies with long follow-up period are needed to confirm the results of this study.

In conclusion, HFX resulted in a high locoregional disease control rate and overall survival rate. A fraction size of 2.25 Gy provided good local control, regardless of the use of SIB. Furthermore, IMRT may reduce toxicity by sparing the carotid artery.
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###### 

Patients and treatment characteristic

  Variable                          All (n = 85)   SIB(--) group   SIB(+) group^[a)](#tfn1-roj-2019-00143){ref-type="table-fn"}^   p-value
  --------------------------------- -------------- --------------- --------------------------------------------------------------- ---------
  Number of patients                85             42              43                                                              
  Age (yr)                                                                                                                         0.911
   ≥65                              44 (51.8)      20 (47.6)       22 (51.2)                                                       
   \<65                             41 (48.2)      22 (52.4)       21 (48.8)                                                       
  Gender                                                                                                                           0.616
   Male                             82 (96.5)      40 (95.2)       42 (97.7)                                                       
   Female                           3 (3.5)        2 (4.8)         1 (2.3)                                                         
  Radiotherapy aim                                                                                                                 0.360
   Definitive                       80 (94.1)      41 (97.6)       39 (90.7)                                                       
   Salvage                          5 (5.9)        1 (2.4)         4 (9.3)                                                         
  Clinical tumor stage                                                                                                             0.012
   cT1                              70 (82.4)      39 (92.9)       31 (72.1)                                                       
   cT2                              15 (17.6)      3 (7.1)         12 (27.9)                                                       
  Anterior commissure involvement                                                                                                  0.156
   Yes                              51 (60.0)      22 (52.4)       29 (67.4)                                                       
   No                               34 (40.0)      20 (47.6)       14 (32.6)                                                       
  Stromal invasion                                                                                                                 0.039
   Yes                              18 (21.2)      5 (11.9)        13 (30.2)                                                       
   No                               67 (78.8)      37 (88.1)       30 (69.8)                                                       
  Radiotherapy technique                                                                                                           \<0.001
   IMRT                             66 (77.6)      23 (54.8)       43 (100)                                                        
   3D CRT                           19 (22.4)      19 (45.2)       0 (0)                                                           
  BED~10~ for the tumor (Gy)                                                                                                       \<0.001
   84.38                            37 (43.5)      0 (0)           37 (86.0)                                                       
   \<84.38                          48 (56.5)      42 (100)        6 (14.0)                                                        

SIB, simultaneous integrated boost; BED~10~, biologically effective dose when α/β ratio was presumed to be 10 for early responding tissue; IMRT, intensity-modulated radiotherapy; 3D CRT, three-dimensional conformal radiotherapy.

SIB dose for the tumor: 67.5 Gy (2.5 Gy per fraction) for 37 patients, 64.8 Gy (2.4 Gy per fraction) for 5 patients, and 62.1 Gy (2.3 Gy per fraction) for 1 patient.

###### 

Univariate and multivariate analyses of factors associated with survival receiving RT with or without SIB

  Variable                                                Locoregional survival      Overall survival                                                                            
  ------------------------------------------------------- -------------------------- ------------------ ----------------------- ------- --------------------------- ------- ---- ----
  Age (yr)                                                0.735 (0.197--2.747)       0.646              \-                      \-      4.935 (0.592--41.106)       0.140   \-   \-
   ≥65                                                                                                                                                                           
   \<65                                                                                                                                                                          
  Gender                                                  0.047 (0.000--93612.288)   0.679              \-                      \-      0.046 (0.000--116071.400)   0.682   \-   \-
   Male                                                                                                                                                                          
   Female                                                                                                                                                                        
  Radiotherapy aim                                        2.970 (0.366--24.101)      0.308              \-                      \-      0.046 (0.000--241644.521)   0.697   \-   \-
   Definitive                                                                                                                                                                    
   Salvage                                                                                                                                                                       
  Clinical tumor stage                                    7.917 (2.104--29.787)      0.002              7.917 (2.104--29.787)   0.002   1.189 (0.142--9.977)        0.873   \-   \-
   cT1                                                                                                                                                                           
   cT2                                                                                                                                                                           
  Anterior commissure involvement                         1.444 (0.361--5.778)       0.603              \-                      \-      1.858 (0.360--9.595)        0.459   \-   \-
   Yes                                                                                                                                                                           
   No                                                                                                                                                                            
  Stromal invasion                                        3.343 (0.895--12.479)      0.073              2.240 (0.535--9.377)    0.270   3.207 (0.716--14.368)       0.128   \-   \-
   Yes                                                                                                                                                                           
   No                                                                                                                                                                            
  Radiotherapy technique                                  0.375 (0.047--3.003)       0.355              \-                      \-      3.006 (0.654--13.811)       0.157   \-   \-
   IMRT                                                                                                                                                                          
   3D CRT                                                                                                                                                                        
  SIB for the tumor                                       0.395 (0.098--1.589)       0.191              \-                      \-      1.436 (0.631--3.267)        0.388   \-   \-
   Yes^[a)](#tfn2-roj-2019-00143){ref-type="table-fn"}^                                                                                                                          
   No                                                                                                                                                                            
  BED~10~ for the tumor (Gy)                              0.275 (0.068--1.112)       0.070              0.520 (0.107--2.538)    0.419   1.210 (0.231--6.328)        0.822   \-   \-
   84.38                                                                                                                                                                         
   \<84.38                                                                                                                                                                       

RT, radiotherapy; SIB, simultaneous integrated boost; HR, hazard ratio; CI, confidence interval; IMRT, intensity-modulated radiotherapy; 3D CRT, three-dimensional conformal radiotherapy; BED~10~, biologically effective dose when α/β ratio was presumed to be 10 for early responding tissue.

SIB dose for the tumor: 67.5 Gy (2.5 Gy per fraction) for 37 patients, 64.8 Gy (2.4 Gy per fraction) for 5 patients, and 62.1 Gy (2.3 Gy per fraction) for 1 patient.

Variables with p \< 0.1 in univariate analysis were included in multivariate analysis.

###### 

Studies of local control according to fraction size and overall treatment for early glottic cancer

  Study                                                                                        No. of patients                                                                                           Clinical stage                                               RT technique                                                     Fraction size (Gy)                                           Total dose (Gy)                                                                                        OTT (day)                        BED~10~ (Gy)                                                                                  5-yr LC (%)
  -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ -------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------
  Ermis et al. \[[@b7-roj-2019-00143]\]                                                        132                                                                                                       T1-2N0                                                       2D/3D                                                            2.75                                                         55                                                                                                     Median 28 (range, 25-            67                                                                                            85.6^[a)](#tfn4-roj-2019-00143){ref-type="table-fn"}^
  Le et al. \[[@b9-roj-2019-00143]\]^[b)](#tfn5-roj-2019-00143){ref-type="table-fn"}^          398                                                                                                       T1-2N0                                                       2D                                                               \<1.8 (n=146)                                                T1: median 63 (range, 46.6--75.4)                                                                      Median 50 (range, 34--75)        Median 74.3 (estimation of the median valu^[e)](#tfn8-roj-2019-00143){ref-type="table-fn"}^   \<1.8: T1 (79), T2 (44)
  1.8--1.99 (n=128)                                                                            1.8--1.99: T1 (92), T2 (79)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  2--2.24 (n=62)                                                                               T2: median 65.2 (range, 51.2--76.6)                                                                       2--2.24: T1 (81), T2 (73)                                                                                                                                                                                                                                                                                                                                                                                                        
  ≥2.5 (n=62)                                                                                  ≥2.5: T1 (94), T2 (100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Yamazaki et al. \[[@b10-roj-2019-00143]\]^[b)](#tfn5-roj-2019-00143){ref-type="table-fn"}^   180                                                                                                       T1N0                                                         2D                                                               CFX: 2                                                       CFX: 60--66 (66 Gy for larger than minimal tumor^^[c)](#tfn6-roj-2019-00143){ref-type="table-fn"}^^)   CFX: 40--47                      CFX: 72--79.2                                                                                 86
  HFX: 2.25                                                                                    HFX: 56.25--63 (63 Gy for larger than minimal tumor^^[c)](#tfn6-roj-2019-00143){ref-type="table-fn"}^^)   HFX: 33--40                                                  HFX: 68.9--77.2                                                  CFX: 76--78                                                                                                                                                                                                                                                                                        
  HFX: 91--92                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Yu et al. \[[@b11-roj-2019-00143]\]^[b)](#tfn5-roj-2019-00143){ref-type="table-fn"}^         126                                                                                                       T1N0                                                         2D                                                               CFX: 2                                                       CFX: 66                                                                                                CFX: 46                          CFX: 79.2                                                                                     78
  HFX: 2.25 or 2.5                                                                             HFX: 65.25 (2.25 Gy per fraction) or 50 (2.5 Gy per fraction)                                             HFX: 40 (2.25 Gy per fraction) or 26 (2.5 Gy per fraction)   HFX: 79.9 (2.25 Gy per fraction) or 62.5 (2.5 Gy per fraction)   CFX: 65.6                                                                                                                                                                                                                                                                                          
  HFX: 84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Fein et al. \[[@b14-roj-2019-00143]\]^[b)](#tfn5-roj-2019-00143){ref-type="table-fn"}^       109                                                                                                       T1-2N0                                                       2D                                                               \<2: T1 (41%), T2 (50%)                                      T1: median 66 (range, 60--70.8)                                                                        T1: median 49 (range, 42--72)    T1: median 79.2                                                                               85
  ≥2: T1 (59%), T2 (50%)                                                                       T2: median 69 (range, 66--76.29)                                                                          T2: median 49 (range, 42--76)                                T2: median 82.8                                                                                                                                                                                                                                                                                                                                                     
  Kim et al. \[[@b15-roj-2019-00143]\]                                                         157                                                                                                       T1-2N0                                                       2D/3D                                                            CFX: 2                                                       CFX: 70                                                                                                CFX: median 50 (range, 47--59)   CFX: 84                                                                                       CFX: 78.3
  HFX: 2.25                                                                                    HFX: 67.5                                                                                                 HFX: median 44 (range, 40--67)                               HFX: 82.7                                                        HFX: 90.8^[d)](#tfn7-roj-2019-00143){ref-type="table-fn"}^                                                                                                                                                                                                                                         
  Moon et al. \[[@b16-roj-2019-00143]\]^[e)](#tfn8-roj-2019-00143){ref-type="table-fn"}^       156                                                                                                       T1-2N0                                                       2D/3D                                                            CFX: 2                                                       CFX: 66 for T1, 70 for T2                                                                              CFX: median 50 (range, 44--60)   CFX: 79.2--84                                                                                 CFX: 77.8
  HFX: 2.25                                                                                    HFX: 63 for T1, 67.5 for T2                                                                               HFX: median 42 (range, 5--63)                                HFX: 77.2--82.7                                                  HFX: 88.5                                                                                                                                                                                                                                                                                          
  Present study                                                                                87                                                                                                        T1-2N0                                                       3D/IMRT (3D: 19, IMRT: 66)                                       2.25 (for the whole larynx)                                  60.75 (2.25 Gy per fraction)                                                                           Median 38 (range, 36--62)        74.42--84.38                                                                                  89.1^[g)](#tfn10-roj-2019-00143){ref-type="table-fn"}^
  2.3--2.5 (49.4%, SIB for the tumor)^^[f)](#tfn9-roj-2019-00143){ref-type="table-fn"}^^       62.1--67.5 (including SIB dos^[e)](#tfn8-roj-2019-00143){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                                                                                                                                                                                             

RT, radiotherapy; OTT, overall treatment time; BED~10~, biologically effective dose when α/β ratio is presumed to be 10 for early responding tissue; LC, local control; CFX, conventionally fractionated radiotherapy; HFX, hypofractionated radiotherapy; IMRT, intensity-modulated radiotherapy; SIB, simultaneous integrated boost.

5-year regional control rate: 95.4%

These studies reported only local control rate.

Minimal tumor: if tumor length is greater than two-thirds of the glottis

One patient who had only regional failure was included in the CFX arm. No patients had only regional failure in the HFX arm.

Five patients had regional recurrence.

SIB dose for tumor: 67.5 Gy (2.5 Gy per fraction) for 37 patients, 64.8 Gy (2.4 Gy per fraction) for 5 patients, and 62.1 Gy (2.3 Gy per fraction) for 1 patient.

5-year locoregional control rate: 88.1% for all patients, 92.3% for SIB(--) group and 84.7% for SIB(+) group, respectively.
